Clinical trialNCT05952804RecruitingPhase 2Interventional

IVIG for Infection Prevention After CAR-T-Cell Therapy

SponsorFred Hutchinson Cancer CenterEnrollment150Hematologic Malignancies

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immunoglobulin G (IgG) antibodies with donor blood product derived IgG antibodies that may help prevent infection. IgG antibodies are often depleted as a result of CAR-T therapy. Giving immunoglobulin replacement therapy may prevent infectious complications in patients receiving CD19 CAR-T cell therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Joshua Hill, MD
Fred Hutch/University of Washington Cancer Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Cancer Center
Duarte, California, United States
Sanjeet Dadwal, MD
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Jay Spiegel, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Frederick Locke, MD
Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Matthew Frigault, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Miguel-Angel Perales, MD
Recruiting
Oregon Health and Science University (ohsu) Knight Cancer Institute
Portland, Oregon, United States
Amrita Desai, MD, MPH
Recruiting
Fred Hutch/university of Washington Cancer Consortium
Seattle, Washington, United States
Joshua Hill, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anti-CD19 CAR T Cells PreparationImmune Globulin Infusion, 10% Solution

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Jun 2024
Primary completion: 31 Jul 2028
Completion: 31 Jul 2028
Last update posted: 29 Jun 2026
Registered enrollment: 150
Registry id: NCT05952804

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.